Clinical Trials Search Results
Results 1-10 of 593 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Keywords/Phrases: | "colorectal cancer" |
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 1190 locations
Age: 18 years and over
Gender: Male or Female
Location: 1190 locations
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 883 locations
Age: 18 years and over
Gender: Male or Female
Location: 883 locations
Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients with Locally Advanced or Metastatic HER2 / Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 694 locations
Age: 18 years and over
Gender: Male or Female
Location: 694 locations
Combination Chemotherapy with or without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 852 locations
Age: 18 years and over
Gender: Male or Female
Location: 852 locations
Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 436 locations
Age: 18 years and over
Gender: Male or Female
Location: 436 locations
Combination Chemotherapy, Bevacizumab, and / or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 365 locations
Age: 18 years and over
Gender: Male or Female
Location: 365 locations
Phase 1 / 2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
Status: Active
Age: 12 years and over
Gender: Male or Female
Location: 30 locations
Age: 12 years and over
Gender: Male or Female
Location: 30 locations
Savolitinib in Treating Participants with MET Amplified Metastatic or Unresectable Colorectal Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 26 locations
Age: 18 years and over
Gender: Male or Female
Location: 26 locations
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 26 locations
Age: 18 years and over
Gender: Male or Female
Location: 26 locations
Neratinib HER Mutation Basket Study (SUMMIT)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Age: 18 years and over
Gender: Male or Female
Location: 25 locations